Brickell Biotech to Participate at Upcoming September Conferences
September 08, 2021 08:30 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing...
Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer
September 01, 2021 07:05 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by...
Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases
September 01, 2021 07:00 ET
|
Brickell Biotech, Inc.
Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 Acquisition includes...
Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
August 16, 2021 08:00 ET
|
Brickell Biotech, Inc.
Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021 NDA submission for sofpironium bromide gel, 15% anticipated in mid-2022 pending Phase 3...
Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 12, 2021 16:01 ET
|
Brickell Biotech, Inc.
Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pivotal Cardigan II study- - -Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies...
Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021
July 29, 2021 08:00 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., July 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter’s Option to Purchase Additional Shares
July 22, 2021 16:05 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., July 22, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), a clinical-stage pharmaceutical company focused on developing innovative and...
Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million
July 19, 2021 22:44 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), clinical-stage pharmaceutical company focused on developing innovative and...
Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock
July 19, 2021 17:25 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative and...
Brickell Biotech to Participate at William Blair’s Biotech Focus Conference 2021
July 06, 2021 08:00 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., July 06, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...